Nasal Sinus Esthesioneuroblastoma: A Case Report

Authors

  • Mossé BA Wilfried Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco  Author
  • El Majjaoui Sana Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author
  • Tayeb Kabdani Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author
  • Elkacemi Hanan Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author
  • Abdou Sara Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author
  • Benmessaoud Houda Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author
  • Siham Jaba Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author
  • Seka Evrard N Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author
  • Kietga Gaêl Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author
  • Compaoré Bertrand Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author
  • Patricia Agbanglanon Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco  Author
  • Nourddine Benjaafar Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco Author

DOI:

https://doi.org/10.47363/JONRR/2020(1)108

Keywords:

Nasal Sinus, Esthesioneuroblastoma

Abstract

Esthesioneuroblastoma (ENB) is a rare malignant neoplasm originating from the olfactory epithelium located in the upper part of the nasal cavities. The treatment is not yet well codified; external surgery and radiotherapy were the standard treatment. We have reported a case of a 20-year-hold patient treated with neoadjuvant chemotherapy, surgery, and then adjuvant chemotherapy. The prognosis of these malignant tumors is similar to that of ethmoid adenocarcinomas and better than that of squamous carcinomas of the facial bone structure. 5-year overall and disease-free survival averaged 45%.

Author Biographies

  • Mossé BA Wilfried, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco 

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco 

  • El Majjaoui Sana, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

  • Tayeb Kabdani, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

  • Elkacemi Hanan, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

  • Abdou Sara, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

  • Benmessaoud Houda, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

  • Siham Jaba, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

  • Seka Evrard N, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

  • Kietga Gaêl, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

  • Compaoré Bertrand, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

  • Patricia Agbanglanon, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco 

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco 

  • Nourddine Benjaafar, Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

    Department of Radiation Oncology, National Institute of Oncology, Mohamed V University, Rabat, Morocco

Downloads

Published

2020-08-31

Issue

Vol. 1 No. 2 (2020): Volume 1 Issue 2

Section

Articles